COMPANY PROFILE / #1998
Converge Bio
Wilmington, DEVenture Capital-Backed
OVERVIEW
Developer of a generative artificial intelligence platform intended for drug discovery and development purposes. The company's platform provides a library of foundation models trained on biological languages such as DNA, RNA, and protein sequences, offering features for antibody design, target identification, biomarker discovery, and protein manufacturing optimization, enabling biotechnology and pharmaceutical organizations to accelerate research cycles and improve the clinical success rate of novel therapies.
已融资30.50
最新估值90.00
员工数49
成立年份2024
公司概况
- Companies
- Converge Bio
- Description
- Developer of a generative artificial intelligence platform intended for drug discovery and development purposes. The company's platform provides a library of foundation models trained on biological languages such as DNA, RNA, and protein sequences, offering features for antibody design, target identification, biomarker discovery, and protein manufacturing optimization, enabling biotechnology and pharmaceutical organizations to accelerate research cycles and improve the clinical success rate of novel therapies.
- Website
- www.converge-bio.com
- HQ Location
- Wilmington, DE
- Year Founded
- 2024
- Keywords
- ai in healthcare, antibody generation, biological data, drug development, generative ai, healthcare ai, integrated ai, llm model, prediction platform, protein engineering
- Competitors
- Xaira Therapeutics, Chai Discovery, Cradle (Healthcare Technology Systems)
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 30.50
- First Financing Date
- 01-Jan-2024
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 03-Jun-2026
- Last Financing Deal Type
- Grant
- Last Financing Size
- 2.50
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 90.00
- Last Known Valuation Date
- 13-Jan-2026
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 144.91
- Valuation Estimate Growth Rate
- 61.01%
- Active Investors
- AuroraAxis Capital, AWS Startups, Bessemer Venture Partners, Gates Foundation, Intel Ignite, Saras Capital, TLV Partners, Vintage (Private Equity)
- # Active Investors
- 8
- Acquirers
- —
团队与联系人
- Employees
- 49
- Employee Growth %
- 48.48%
- Employee History
- 2026: 49, 2025: 33
- Primary Contact
- Dov Gertz
- Primary Contact Title
- Co-Founder, Chief Executive Officer & Board Member
- Primary Contact Email
- dov@converge-bio.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.72%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 96
- Size Multiple
- 5.41x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 82
- Majestic Referring Domains
- 189
- SimilarWeb Unique Visitors
- 273
- SimilarWeb Unique Visitors Change
- -64
- SimilarWeb Growth Rate
- -0.74%
- SimilarWeb Growth Rate Percentile
- 8
- Success Probability Over Time – 1 Year
- 2%
- Success Probability Over Time – 3 Year
- 16%
- Success Probability Over Time – 5 Year
- 28%
记录来源：public.companies · 原始序号 #1998 · 所有字段均按数据库原值展示。